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In the investigation of lymphoproliferative disor-
ders, the cellular immunologist has four broad 
objectives: first, identification of common mem-
brane and functional properties of the neoplastic 
cells of individual disorders to facilitate improved 
classification of the lymphomas; second, recogni-
tion of distinguishing features of the neoplastic 
cells to permit development of more specific thera-
peutic approaches to the management of affected 
patients; third, identification of certain of the 
manifestations of the lymphomas that might be 
neoplastic amplifications of normal phenomena, 
perhaps not otherwise noticed; and finally, acquisi-
tion of large homogeneous populations of lympho-
cytes, which often provide unique reagents for the 
investigation of numerous aspects of basic im-
munobiology. 
During the past three years, the remarkable 
story of the cutaneous lymphomas has begun to 
unfold rapidly. As will be discussed, application of 
immunologic methods to the study of this group of 
disorders has already permitted a much improved 
classification, more efficient clinical management, 
recognition of a special skin-thymus interaction, 
and several scientific advances. 
BACKGROUND 
The term "cutaneous lymphomas" refers to 
those lymphoproliferative disorders characterized 
by widespread and perhaps primary skin involve-
ment. These processes include mycosis fungoides 
[1-3], the Sezary syndrome [4-6], and several 
disorders which previously were difficult to classify 
[7]. Much controversy and confusion over the 
classification of these diseases have been propa-
gated by the purely descriptive or eponymic titles 
given to them. Because of the T-cell features of the 
neoplastic cells in each of these disorders, it will be 
proposed in this paper that they be reclassified as 
"cutaneous T-cell lymphomas." 
The neoplastic cells of these disorders have been 
studied in terms of both their membrane and 
functional characteristics. During differentiation, 
thymus-derived lymphocytes (T-cells) and bone 
marrow-derived lymphocytes (B-cells) acquire dis-
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tinguishing membrane properties which usually 
permit their accurate identification [8]. T -cells 
have receptors for uncoated sheep erythrocytes; 
because of these receptors, under appropriate ex-
perimental conditions sheep erythrocytes adhere to 
T -cells to form rosettes. T -cells also bear specific 
membrane antigenic determinants, usually 
referred to as human thymic lymphocyte antigen 
(HTLA). These cells can therefore be selectively 
lysed by specific antiserum in the presence of 
complement. Classical B-cells lack both of these 
properties. Instead, they bear easily detectable 
immunoglobulin, have receptors for the cleaved 
third component of complement, and bind aggre-
gated IgG, apparently because of receptors for the 
Fc fragment of this immunoglobulin class. 
CHARACTERIZATION OF CUTANEOUS LYMPHOMAS 
The first question which we asked was: Do the 
neoplastic cells of the cutaneous lymphomas share 
common features? A prerequisite to the study of 
disorders with a significant infiltrative component 
was the development of a method which permitted 
identification of the mononuclear cells infiltrating 
soft tissues. This accomplishment has been re-
ported in detail previously [9). Briefly, sheep 
erythrocytes bearing a surface coat of complement 
will adhere in frozen sections to B-cells and some 
histiocytes through rece,Ptors those cells have for 
C3. Sheep erythrocytes bearing a surface coat of 
IgG will adhere in frozen sections to cells of the 
mononuclear phagocyte series through receptors 
those cells have for the Fc fragment of IgG. T -cells 
are identified as described above, after their ex-
traction from tissues. 
Since our first report [9], this method has been 
used extensively to investigate a broad spectrum of 
lymphoproliferative [10] and inflammatory [9,11] 
disorders and to identify complement receptors in 
normal human glomeruli [12]. 
The easiest patients to study are those in the 
leukemic phase of their disease: abnormal circulat-
ing cells are readily obtained and results can be 
correlated with those from study of infiltrated 
tissues. During the past three years, we have 
studied intensively 10 patients with generalized 
erythroderma and lymphocytic leukemia. The 
patient population was not limited to those with 
the classical Sezary syndrome, but included 4 
patients referred with a diagnosis of chronic lym-
phocytic leukemia and 1 with a diagnosis of 
"atypical lymphoma, leukemic phase." These 5 
patients are representative of the 'approximately 
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2% of patients with lymphocytic leukemia reported 
to have associated erythroderma [13,14). Our goal 
was to determine whether erythroderma is a 
cutaneous marker for a common cellular denomi-
nation in the neoplastic lymphocytes. The results 
are summarized in Table 1. Although the leukemic 
lymphocytes from more than 95% of patients with 
classical chronic lymphocytic leukemia reported in 
the literature (reviewed in [15]) and from all of our 
patients with classical chronic lymphocytic leu-
kemia without associated erythroderma had mem-
brane properties characteristic of B-cells, most of 
the leukemic cells from each of our patients 
with lymphocytic leukemia and erythroderma had 
membrane properties characteristic of T -cells. 
Three morphologic types of leukemia were found 
(Tab. 1). The peripheral blood findings from the 
study of patients with the classical and small cell 
variants of the Sezary syndrome are in agreement 
with those previously reported by us [15] and 
others [16-18]. Cells from patient 1 were unusual 
in that they had receptors for C3, a property of 
B-cells, in addition to their T-cell membrane 
features. Because approximately 2% of peripheral 
blood lymphocytes from normal individuals also 
fall into this "twilight zone," it is possible that 
patient 1 's leukemia arose from such a normal 
population. 
Cells infiltrating skin in 8 of the 10 patients with 
erythroderma and T -cell leukemia were studied by 
the method described above. Also, an involved 
lymph node from patient 2 was studied. In all 
cases, the infiltrating cells were identified as T-
cells. 
Mycosis fungoides and lymphomatoid papulosis, 
two disorders considered by many investigators to 
be related to the Sezary syndrome (see [7]) were 
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also examined. As shown in Table II, the majority 
of infiltrating cells that could be positively identi-
fied had T-cell properties. 
In summary, several cutaneous lymphoprolifera-
tive disorders were studied. In each instance, the 
abnormal cells had those features which are char-
acteristic of T -cells. The leukemic cells in each of 3 
morphologic variants of leukemia distinguished by 
erythroderma also had T-cell membrane proper-
ties, although cells from 1 patient had a B-cell 
property as well. 
These results strongly support a relationship 
between these disorders (the small cell and classi-
cal variants of the Sezary syndrome, a previously 
undescribed leukemia, mycosis fungoides, and 
lymphomatoid papulosis) and suggest that they be 
classified together under the heading "cutaneous 
T-cell lymphomas." 
FUNCTIONAL STUDIES 
The functional capabilities of leukemic T -cells 
from the 8 patients described in Table I were 
extensively investigated. In addition to a prolifera-
tive response to the mitogens phytohemagglutinin, 
pokeweed, and concanavalin A and to a battery of 
antigens, the reactivity of the neoplastic T -cells in 
mixed leukocyte and in cell-mediated lympholysis 
cultures were determined. Furthermore, their abil-
ity to serve as effector cells in antibody-dependent 
cell lysis reactions, their proliferative response to 
anti -T-cell serum and blastogenic factor, and their 
production of lymphokines were determined. 
These findings have been extensively described in 
separate reports [7,15,19,20]. Three broad state-
ments, however, can be made here. First, the 
neoplastic T -cells from each of these patients were 
shown to be functionally abnormal. Second, leu-
TABLE I. Percent of peripheral blood mononuclear cells with surface markersa 
Percent of cells with membrane properties 
Patient T-cell markers B-cell markers Monocyte 
marker 
E + HTLA IgM EAC + SIg IgG EA + 
Atypical leukemia 
1 225000/97 74 86 68 1 1 
Small cell Sezary variant 
2 157000/95 66 89 2 1 1 
3 37000/87 86 93 5 3 2 
4 46000/82 82 95 4 3 3 
5 21200/52 78 82 5 ND 5 
Large cell Sezary variant 
6 12500/66 80 ND 16 18 5 
7 24000/72 85 ND 3 ND 2 
8 13500/90 88 ND 4 ND 3 
9 35000/88 35 72 5 ND 2 
10 19500/92 20 83 4 ND 5 
Chronic lymphocytic leukemia (5 subjects) 5 5 80 95 2 
Normal (12 subjects) 61 70 11 20 13 
a E = sheep erythrocytes; A = antibody against sheep erythrocytes (Forssman antigen); C = complement; SIg = % 
surface immunoglobulin-bearing cells; HTLA = % human thymic lymphocyte antigen positive cells; + = % 
rosette-forming cells; ND = not done. 
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TABLE II. Nature of infiltrate in mycosis fungoides and lymphomatoid papulosisa 
Patient 
11 
12 
13 
14 
15 
16 
17 
18 
Diagnosis 
Mycosis fungoides 
Pulmonary lymphoma (nodule) 
Mycosis fungoides 
Mycosis fungoides 
Lymphomatoid papulosis 
Mycosis fungoides 
Lymphomatoid papulosis 
Lymphomatoid papulosis 
Lymphomatoid papulosis 
Lymphomatoid papulosis 
Cryosection studies Suspension 
studies 
IgM EAC IgGEA Eb 
Neg Neg 96 
Neg Neg 96 
Neg Neg 94 
Neg Neg 91 
Neg Neg 92 
Neg Neg 96 
Neg Neg 90 
Neg Neg ND 
Neg Neg ND 
Neg Neg ND 
a IgM EAC = IgM antibody-erythrocyte-complement complexes; IgG EA = IgG antibody-erythrocyte complexes; 
E = sheep erythrocytes, neuraminidase pretreated; ND = Not done. 
b Percent E-rosette-forming cells. 
kemic T -cells from each patient reacted differently 
from cells of all other patients, indicative of the 
heterogenicity of the group. Finally, because of the 
selective functional abnormalities, each popula-
tion of leukemic T -cells is in essence a reservoir of 
cellular reagents invaluable for work in such varied 
areas of lymphocyte physiology as characterization 
of lymphocyte membrane receptors, identification 
of mechanisms of lymphocyte triggering, and puri-
fication of anti-T-cell immunoglobulin from the 
plasma of patients with lupus erythematosus. 
One of these findings, the spontaneous produc-
tion of macrophage inhibitory factor [5] by the 
leukemic T -cells [19], may be of clinical as well as 
scientific significance. As shown in Figure 1, serum 
from each of 6 patients with T-cell leukemia and 
erythroderma contained identifiable migration-
inhibitory factor (MIF). In all but 1 case, using 
greater than 20% inhibition of macrophage migra-
tion as a rigid criterion of positivity, the factor 
could be traced back to the leukemic T -cells. -The 
clinical relevance of this finding will be discussed 
in the next section. 
CONCLUSION 
From the accumulated evidence, unified con-
cepts about several aspects of the disorders under 
discussion can be developed (Fig. 2). First, the 
large and small cell variants of the Sezary syn-
drome, mycosis fungoides, and related lympho-
proliferative disorders can be classified under the 
broad heading "cutaneous T-cell lymphomas." In 
all instances, these processes clinically appear to 
originate in the skin and spare the thymus [21]. 
Whether these abnormal T -cells actually undergo 
final differentiation in the skin or preferentially 
migrate to that tissue is an important, but as yet 
unanswered, question. Clearly, however, wide-
spread cutaneous infiltration is a marker of at least 
certain types of lymphoproliferative disorders . 
In certain cases, the cutaneous T-cell lym-
phomas progress to frank leukemia. In such leu-
kemic patients, clinical sequelae can be largely 
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FIG. 1. Macrophage migration inhibitory factor m 
patients with cutaneous T-cell lymphoma, leukemic 
phase. In serum assay, test serum is added to medium. In 
direct assay, test lymphocytes are added to migrating 
guinea-pig macrophages. In indirect assay, supernatants 
from short-term cultures of test lymphocytes are added to 
medium in which the macrophages migrate. 
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FIG. 2. Effects traceable to leukemic T -cells of cutane-
ous T-cell lymphomas. 
traced to the properties of the neoplastic cells. The 
most obvious morbidity is secondary to the tissue 
distribution of these T -cells. Significantly, these 
abnormal T -cells, like their normal counterparts, 
tend to localize in specific regions of soft tissues. In 
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addition to their preferential infiltration of the skin 
and T-cell zones of lymphoid tissue, they spare the 
bone marrow to a remarkable extent [15]. Whereas 
B-cell leukemias significantly involve the bone 
marrow, replacing normal marrow elements [22], 
the neoplastic cells of the cutaneous T-cell leu-
kemias involve the bone marrow only to a limited 
extent, probably reflecting both their extramedul-
lary production and a tendency not to migrate to 
the marrow. Therefore, even despite extreme pe-
ripheral blood lymphocytosis in individual cases, 
" severe anemi"a, granulocytopenia, and throm-
bocytopenia are not prominent features of these 
T -cell leukemias. Indeed, in addition to wide-
spread cutaneous infiltration, surprising sparing of 
marrow in patients suspected of having chronic 
lymphocytic leukemia should alert the physician 
to the possibility of aT-cell leukemia. 
A number of more subtle influences on the host's 
immunocompetence can also be traced to the 
neoplastic T -cells. First, as indicated earlier, 
serum from each patient with cutaneous T-cell 
leukemia studied contained significant quantities 
of macrophage inhibitory factor, MIF, produced in 
large measure by the leukemic cells. Animal stud-
ies [23] indicate that intravenously administered 
MIF significantly suppresses the ability of the host 
to express delayed hypersensitivity. In that study, 
the presence of MIF in peripheral blood caused a 
marked monocytopenia, probably secondary to 
adherence of monocytes to vascular endothelium. 
Therefore, at least two reasons for the clinically 
observed suppression of T -cell-mediated immunity 
in patients with cutaneous T-cell lymphoma, leu-
kemic phase, have been identified. First, normal 
T -cells capable of responding to foreign antigens 
are replaced in the peripheral blood by nonreactive 
leukemic T -cells. Second, serum MIF adversely 
affects the ability of peripheral blood monocytes to 
mobilize. These leukemias can be considered T-
cell analogs of multiple myeloma, with the cellular 
product in this instance being MIF rather than 
immunoglobulin. 
Two other findings may also be important. With 
Waldmann [24], we have studied leukemic T -cells 
from one of our patients and found that these cells 
had the remarkable property of reversing the 
inability of B-cells from a patient with hypogam-
maglobulinemia to develop into immunoglobulin-
secreting cells after stimulation in vitro with poke-
weed mitogen. Of particular interest, that patient 
also had a profound thymic deficiency, manifested 
by absence of delayed hypersensitivity on skin 
testing, markedly decreased in vitro response to 
mitogens and antigens, failure to reject grafted 
allogeneic skin, and few peripheral blood lympho-
cytes with T-cell membrane properties. On the 
other hand and despite the hypogammaglobuline-
mia, that patient had near-normal peripheral blood 
B-cell levels. It seems most likely that the leuke-
mic T -cells from our patient permitted B-cells 
from the patient of Waldmann and co-workers to 
differentiate into immunoglobulin-secreting cells 
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by providing a specific, previously absent, cellular 
function. This observation may be important for 
two reasons. First, unlike patients afflicted with B-
cell leukemia, patients with cutaneous T-cell lym-
phoma, leukemic phase, have normal or increased 
levels of serum immunoglobulins. In addition, pa-
tients with mycosis fungoides often have elevated 
levels of IgA [25], and our patients with the Sezary 
syndrome often have elevated levels of IgE. Pro-
duction of both of these classes of immunoglobulin 
may be particularly T -celi dependent. Since the 
absolute numbers of peripheral blood B-cells in 
patients with cutaneous T-cell lymphomas are 
often decreased, these observations may reflect a 
facilitation of immunoglobulin production by resi-
dual B-cells. Individuallymphoproliferative disor-
ders may be neoplasms of lymphocytes of individ-
ual cellular subclasses. It is therefore possible that 
these cutaneous T -cell neoplasms are derived from 
normal precursors which have a tendency to mi-
grate to the skin and which subserve a lymphocyte 
function as described above. 
The second observation is that an extract of 
Sezary cells, unlike that from normal mononuclear 
cells, lacked chemotactic properties for other leu-
kocytes [26]. This lack may further compromise 
the ability of the host to mobilize normal leuko-
cytes to superinfected regions in collections of 
neoplastic T -cells, a major cause of morbidity in 
patients with mycosis fungoides [2]. 
In devising new therapeutic approaches to the 
management of patients with cutaneous T-cell 
lymphoma, we have exploited the distinctive fea-
tures of the neoplastic T -cells. Five such features 
appear to be particularly important: the migratory 
patterns of these cells, the bone-marrow sparing, 
the slow spontaneous rate of replication of the 
neoplastic cells, the T-cell membrane antigens of 
these cells, and the presence or absence of a 
leukemic phase. Evidence, to date largely circum-
stantial, has accumulated suggesting that the neo-
plastic T -cells in these patients resemble normal 
T -cells in their propensity to recirculate through 
the body. Rappaport and Thomas have reported 
that once mycosis fungoides escapes the skin, the 
lymph nodes are not effective barriers against 
spread to other tissues [27]. Of special interest, a 
remarkable spontaneous cyclicity was observed in 
one of our patients, with the peripheral blood 
lymphocyte count and cutaneous infiltration vary-
ing inversely. No evidence (increased urinary xan-
thines, antilymphocyte serum factors) was identi-
fied to suggest rapid cellular destruction during the 
phase in which the count dropped. It therefore 
seems probable that, secondary to as yet unidenti-
fied factors, the neoplastic T -cells were migrating 
to or emigrating from the skin in a tidal fashion. 
As described in a preliminary report [28], we 
intensively leukapheresed that patient. Leuka-
pheresis is a procedure by which anticoagulated 
peripheral blood is pumped through a continuous 
flow centrifuge, and leukocytes are removed from 
the buffy coat [29]. At the time that the leuka-
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pheresis was initiated, the patient's peripheral 
blood leukocyte count was 216,000 per mm 3 (nearly 
all of which were small Sezary cells) and his 
cutaneous disease was tumor-stage mycosis fung-
oides superimposed on an exfoliative erythro-
derma. His disease had previously progressed de-
spite intensive chemotherapy involving several 
combinations of agents. Twelve procedures were 
performed over a I-month period with complete 
resolution of his cutaneous lesions and a drop in 
his peripheral blood lymphocyte count to 21,000 
per mm 3 • During that course, 36 x 1011 leuko-
cytes were removed. Over the past 24 months, this 
process has been repeated 7 times (averaging 6 
leukaphereses per course), and the patient has 
been kept under good clinical control with no con-
comitant chemotherapy or radiotherapy. Early re-
sults from leuka pheresis of 2 other patients are 
also promising. 
The reasons that leukapheresis is efficacious in 
cutaneous T -cell leukemia are probably as follows. 
First, the neoplastic T -cells appear to migrate 
rapidly between soft tissue depots and blood. By 
removing them in sufficient quantity from the 
blood, an equilibrium is shifted and a relative 
emigration of cells from infiltrated tissue is ef-
fected. Because of the usual slow rate of division of 
these cells, it is possible to remove them much 
more rapidly than they are being produced. 
Because the bone marrow reserve is largely intact, 
the obligatory loss of red blood cells, granulocytes , 
and platelets which occurs during intensive leuka-
pheresis can be readily replaced in the peripheral 
blood. 
In vivo kinetic studies are currently in progress, 
and it is anticipated that they will enable us to 
determine not only the site(s) of proliferation of the 
neoplastic T -cells but also whether drastic reduc-
tion of tumor 'load in these patients leads to an 
increased mitotic rate by the residual abnormal 
cells and, therefore, increased susceptibility to 
antimitotic chemotherapeutic agents . In selected 
cases and under carefully controlled conditions, 
administration of specific anti -T-cell sera might 
also be of value, either alone or in combination 
with other agents . 
The cutaneous T-cell lymphomas provide three 
groups of exciting challenges. First, it is already 
clear that investigation of the properties of the 
neoplastic cells in these disorders can be translated 
into improved understanding of the pathogenetic 
mechanisms underlying their diverse manifesta-
tions and better clinical management of affected 
patients. Because of the prominent skin involve-
ment and the accessibility of that tissue for study, 
these disorders provide rare opportunities to clarify 
mechanisms of tumor cell homing patterns and the 
relation of leukemic and aleukemic phases of 
lym phoproliferative processes. 
Second, as sources of large homogeneous popula-
tions of differentiated T -cells, the leukemic phases 
of the cutaneous T -cell leukemias are invaluable in 
the study of many aspects of basic and clinical 
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immunobiology. Finally, and perhaps most impor-
tant, the existence of such a group of lymphoprolif-
erative disorders suggests a very special relation-
ship between at least certain subpopulations of 
T -cells and the skin . It is notable that each of these 
processes (three morphologic types of lymphocytic 
leukemia, mycosis fungoides, and lymphomatoid 
papulosis) selected for study because of the promi-
nent and apparently primary skin involvement has 
been demonstrated to be of T-cell origin. Further-
more, one of the most characteristic histologic 
findings in all of our cases was an "epitheliotro-
pism" of the atypical cells, forming either intraepi-
dermal clusters (Pautrier's microabscesses) or sin-
gle cell pockets. It will be important to discover 
whether what we recognize as cutaneous lym-
phomas are merely neoplastic amplifications of a 
normal skin-T-cell interaction, the homing in the 
skin of a population of T -cells which may even 
undergo terminal differentiation in that site and 
which normally subserve specific immunologic 
function(s). In this respect, three findings in exper-
imental animals may be more than coincidental: 
murine T -cells and epidermal cells share specific 
membrane antigenic determinants [30]; Hassall's 
corpuscles in the thymus morphologically appear 
to contain cornifying squamous epithelium identi-
cal to skin [31]; and inbred "nude" athymic mice 
derived their name from their markedly abnormal 
development of the epidermal derivative, hair [32]. 
SUMMARY 
The common cellular denominator of the neo-
plastic lymphocytes of the cutaneous lymphomas 
is the presence of membrane markers of T-cell 
identity. For this reason these disorders are 
grouped together as "cutaneous T cell lym-
phomas ." These neoplastic T -cells have a charac-
teristic tissue distribution (preferentially infiltrat-
ing the skin and sparing the bone marrow). The 
abnormal T -cells of the leukemic phase of these 
disorders produce large amounts of macrophage 
migration inhibitory factor, which may adversely 
affect macrophage mobilization, and also stimu-
late differentiation of B-cells into plasma cells. 
The antigenic properties, the usual slow rate of 
replication, and the circulatory route of these cells 
may be exploitable in the development of more 
specific therapeutic approaches to the c,manage-
ment of affected patients. Although these T -cells 
have an affinity for the skin, the role of this organ 
in the proliferation and differentiation of these 
cells is as yet not established. Localization of 
the primary site(s) of proliferation awaits comple-
tion of in vivo kinetic studies. The neoplastic 
T -cells from such patients provide important cellu-
lar reagents for the study of diverse aspects of 
lymphocyte biology. They have already been used 
to investigate mechanisms of lymphocyte trigger-
ing, isolate histocompatability antigens, and char-
acterize anti-T -cell immunoglobulin from patients 
with systemic lupus erythematosus. ' 
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DISCUSSION 
Gigli: If there is an equilibrium between lymphocytes 
in the circulation and the tissue infiltrate, how can you 
explain Sezary syndrome patients who present very 
moderate elevation of peripheral lymphocytes and 
marked tissue infiltrate? 
Edelson: We are attacking that problem with two 
types of kinetic studies. In collaboration with Chendra 
and associates at Brookhaven National Laboratory, we 
have transfused leukemic cells labeled with tritiated 
cytidine back into a patient. In collaboration with Bunn 
and Shackney at the NCI, we have given pulses of 
intravenous tritiated thymidine to 3 patients, before and 
after leukapheresis. In both studies sequential skin biop-
sies and blood samplings were taken and studied by 
autoradiography. We hope, through these kinetic studies, 
to determine whether the cells preferentially proliferate 
in the skin and to quantitate the dynamics of the postu-
lated equilibrium between the vascular and tissue pools 
of the neoplastic T -cells. 
Kirkpatrick: There are two additional facets of the 
Sezary syndrome that are of immunologic interest. As Dr. 
Edelson mentioned, an MIF -like substance may be found 
in the seurm. In some respects the Sezary syndrome may 
be a T-cell analog of multiple myeloma. That is, the 
patients have excessive production and circulation of 
effector molecules of cell-mediated immunity . Secondly, 
many patients with the Sezary syndrome have cutaneous 
anergy, but, in some cases their lymphocytes respond to 
antigens in vitro with increased DNA synthesis or lym-
phokine production. It is possible that the systemic 
circulation of lymphokines prevents them from develop-
ing the necessary gradients of mediators that are required 
for localized immunologic inflammation such as skin-test 
responses. 
Weston: I would like to comment on the finding of 
lymphokine activity (MIF) in the serum of patients with 
T -cell lymphomas. You speculate that j circulating 
MIF may impair mobilization of blood monocytes, mak-
ing them unavailable for tissue sites. We have prelimi-
nary evidence that, indeed, 10 of 11 mycosis fungoides 
patients have severely depressed cellular chemotaxis of 
their blood monocytes. This is not associated with an 
inhibitor and may be analogous to the situation where 
large amounts of lymphocyte-derived chemotactic factor 
"deactivate" blood monocytes, making them unrespon-
sive to further chemotactic stimuli. 
Lazarus: What is the nature of the histiocyte marker? 
Edelson: For the sake of simplicity, I have referred to 
IgG EA as our histiocyte reagent. Although B-cells also 
have receptors for the Fc fragment ofIgG, IgG EA (as we 
prepare it) appears to bind selectively to histiocytes in 
tissue sections. This observation probably reflects either 
increased numbers or increased avidity of the histiocyte 
Fc receptors. 
